Read more

December 14, 2022
1 min read
Save

Top in endocrinology: Thyroid cancer risk; time-restricted eating

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A recent study found that patients with type 2 diabetes who used a GLP-1 receptor agonist for more than 1 year had an increased risk for thyroid cancer compared with non-users.

Researchers reported that 12% of adults with type 2 diabetes who developed thyroid cancer had used GLP-1 receptor agonists compared with 9.6% of matched controls without thyroid cancer. In both groups, more than 80% of participants used liraglutide (Victoza, Novo Nordisk). It was the top story in endocrinology last week.

Various healthy and unhealthy foods
Time-restricted eating patterns were associated with a minimal difference in weight loss compared with normal eating patterns among patients with obesity. Source: Adobe Stock

Another top story was about data that suggest time-restricted eating does not result in significant weight loss among patients with obesity. Max Petersen, MD, PhD, reported that, on average, time-restricted eating alone was associated with a less than 5% weight reduction among adults with obesity — “not enough to generate significant improvements in cardiometabolic health.”

Read these and more top stories in endocrinology below:

GLP-1 receptor agonist use for more than 1 year may increase thyroid cancer risk

Adults with type 2 diabetes who use a GLP-1 receptor agonist for more than 1 year may have an increased risk for thyroid cancer, according to findings published in Diabetes Care. Read more.

Time-restricted eating does not confer ‘clinically significant’ weight loss in obesity

Time-restricted eating interventions, especially those with an eating window of 8 hours or longer, are not associated with weight loss of 5% or greater for most adults with obesity, according to a speaker at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease. Read more.

Next-generation Dexcom G7 CGM receives FDA clearance for use in type 1 and type 2 diabetes

The FDA has granted clearance to a next-generation continuous glucose monitoring system for people with all types of diabetes aged 2 years and older, according to a press release. Read more.

Global increase in type 2 diabetes rates for adolescents, young adults in past 3 decades

Type 2 diabetes rates and associated number of years lost due to poor health, disability or early death increased substantially among adolescents and young adults from 1990 to 2019, particularly in low- and low-middle income countries. Read more.

More weight lost with automated internet program vs usual primary care

Primary care provider referral to an automated weight-loss program resulted in significantly increased weight loss at 6 and 12 months vs. usual care, according to study findings published in Obesity. Read more.